carbapenems has been researched along with sitafloxacin in 4 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (sitafloxacin) | Trials (sitafloxacin) | Recent Studies (post-2010) (sitafloxacin) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 185 | 22 | 85 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Kaneko, T; Kato, N; Liu, CX; Sakata, T; Watanabe, K | 1 |
Thamlikitkul, V; Tiengrim, S | 1 |
Chang, SC; Chuang, YC; Huang, YS; Sheng, WH; Wang, JT | 1 |
Guo, S; Li, X; Li, Y; Shao, J; Tian, M; Tong, H; Wei, M; Xu, B; Yan, B | 1 |
4 other study(ies) available for carbapenems and sitafloxacin
Article | Year |
---|---|
Impact of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal microflora.
Topics: Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Carbapenems; Cecum; Fluoroquinolones; Male; Mice; Prodrugs; Rats; Rats, Wistar | 2000 |
In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Asia, Southeastern; beta-Lactam Resistance; Carbapenems; Cross Infection; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2013 |
Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; DNA, Bacterial; DNA, Intergenic; DNA, Ribosomal; Fluoroquinolones; Humans; Microbial Sensitivity Tests; RNA, Ribosomal, 16S; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2015 |
Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin | 2022 |